Skip to content
Credit reportVerdict and grounds
Made on 19-11-2026 at 04:19
Reference CK-0683469918-20261119

Storms Pharma

ActivePrivate limited company0683.469.918Leo Kempenaersstraat 7, 2223 Heist-op-den-Berg
Activities of holding companies (NACE 64210) · founded in 2017 · one director

Sources: the KBO register on 19-11-2026; the National Bank, 2025 annual accounts filed on 03-07-2026; the Belgian Official Gazette, latest deed of 25-10-2021.

Credit verdict
Checked score
No score
A financial institution falls outside the model. No bankruptcy probability for this sector.
Bankruptcy probability within 12 months
Checked computes no bankruptcy probability for this sector.
Gross margin
€77,174
▲ 24.3% against 2024
Net result
€249,362
▲ 35.9% against 2024
Equity
€1.0m
▲ 32.0% against 2024
Cash
€14,370
▼ 41.5% against 2024

Grounds

the facts the verdict rests on, each with its source
  1. Storms Pharma made a profit in every financial year since 2018.Annual accounts 2018 to 2025 page 2
  2. Equity stands at €1.0m, or 50.6% of the balance sheet total of €2.0m. That is more than 59% of the 7,187 companies in the financial services sector (NACE 64).Annual accounts 2025 page 2
  3. Cash fell from €24,582 to €14,370.Annual accounts 2024 and 2025 page 2
  4. Of the €1.0m of debt, €528,461 runs for more than a year.Annual accounts 2025, notes page 2
  5. The last five annual accounts came in on time. The 2025 accounts were filed 28 days before the end of the term.National Bank, filing of 03-07-2026 page 5

Representation

The sole director, , represents Storms Pharma alone.

Articles of association, Belgian Official Gazette of 25-10-2021, deed 21363056

Ownership

holds 999 shares. There is one other shareholder.

Deed of 20-10-2017

Storms Pharma · 0683.469.918 · credit report of 19-11-2026Page 1 of 6
Storms Pharma0683.469.918 · report of 19-11-2026

Financial situation

Annual accounts 2021 to 2025, as filed with the National Bank

Gross margin and net resultin €m

20210.0620220.0620230.0620240.0620250.0820210.120220.220230.220240.220250.2
gross marginnet result

Equity and debtsin €m

202120222023202420251.01.0
equitydebts

Cashin €m

20210.0020220.0220230.0220240.0220250.01
on the balance sheet date
Financial year20212022202320242025Trend
Results
Gross margin€59,613€57,330€63,711€62,102€77,174
Operating result€57,473€56,007€61,826€60,442€75,627
Net result€117,585€204,173€174,146€183,555€249,362
Balance sheet at the closing date
Equity€480,053€669,227€823,373€778,197€1.0m
Debts€1.5m€1.4m€1.2m€1.2m€1.0m
Debts due after more than one year€1.3m€1.2m€908,916€794,374€528,461
Debts due within one year€183,307€142,549€282,920€448,282€463,048
Cash€3,540€16,833€19,828€24,582€14,370
Balance sheet total€2.0m€2.1m€2.0m€2.0m€2.0m
Ratios
Solvency23.7%32.6%40.7%38.4%50.6%
Liquidity0.140.420.090.070.07

Source: Annual accounts 2025, abbreviated format, filed on 03-07-2026 (2026-00253449); Annual accounts 2024, abbreviated format, filed on 01-07-2025 (2025-00229833); Annual accounts 2021 to 2023, filed from 25-07-2022 to 11-07-2024 (2022-20220059, 2023-00214085, 2024-00237784).

The operating result of 2025 is 25% higher than in 2024.

Debts fell by €244,391 in 2025.

The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.

Storms Pharma · 0683.469.918 · credit report of 19-11-2026Page 2 of 6
Storms Pharma0683.469.918 · report of 19-11-2026

Board, signature and ownership

Position on 19-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts

Who represents the company

The sole director, , represents Storms Pharma alone.

Articles of association, Belgian Official Gazette of 25-10-2021, deed 21363056

Board

one director in office
Director (not named in the articles)appointed by deed of 25-10-2021
deed of 25-10-2021

Ownership and group

Shareholders

holds 999 shares. holds 1 share.

Deed of 20-10-2017

Board changes

changes role from manager to director.

Gazette, deed 21363056
Storms Pharma · 0683.469.918 · credit report of 19-11-2026Page 3 of 6
Storms Pharma0683.469.918 · report of 19-11-2026

Holdings

Storms Pharma has 1 direct subsidiary (own 2025 accounts).

Country Company Equity Result
Belgium 1
BE 99.82% €423,279 result €234,765

Source: List of holdings in its own 2025 accounts. Every holding stands with its own latest accounts.

Storms Pharma · 0683.469.918 · credit report of 19-11-2026Page 4 of 6
Storms Pharma0683.469.918 · report of 19-11-2026

Events and comparison

The latest events, newest first

Annual accounts 2025 filed, 28 days before the deadline.

NBB filing

Equity above €1m. Equity rises from €778,197 to €1.0m.

Financial

Annual accounts 2024 filed, 30 days before the deadline.

NBB filing

Annual accounts 2023 filed, 20 days before the deadline.

NBB filing

Registered in the Peppol Directory. Reachable for e-invoices through 0208:0683469918.

Annual accounts 2022 filed, 25 days before the deadline.

NBB filing

Equity above €500,000. With a profit in every financial year since 2018, equity grows to €669,227.

Financial

Annual accounts 2021 filed, 6 days before the deadline.

NBB filing

changes role from manager to director.

Gazette, deed 21363056

Annual accounts 2020 filed, 15 days before the deadline.

NBB filing

Annual accounts 2019 filed, 31 days late.

NBB filing

Highest result from 2018 to 2025. The operating result of €78,289 and the net result of €268,223 are both a record.

Financial

Equity above €200,000. With a profit in every financial year since 2018, equity grows to €343,301.

Financial

Annual accounts 2018 filed, 16 days before the deadline.

NBB filing

In 2025, Storms Pharma had a higher net result than 78% of the 7,185 companies in the financial services sector (NACE 64).

Other findings

Peppol

Reachable for e-invoices since 24-11-2023, under 0208:0683469918.

Sanctions lists

Storms Pharma · 0683.469.918 · credit report of 19-11-2026Page 5 of 6
Storms Pharma0683.469.918 · report of 19-11-2026

Sources and method

Where each fact in this report comes from

SourceWhatDateReference
KBO registerRegistration, legal situation, activity, establishment units19-11-2026KBO 0683.469.918
National Bank of BelgiumAnnual accounts 2025, abbreviated format03-07-20262026-00253449
National Bank of BelgiumAnnual accounts 2024, abbreviated format01-07-20252025-00229833
National Bank of BelgiumAnnual accounts 2021 to 202325-07-2022 to 11-07-20242022-20220059, 2023-00214085, 2024-00237784
Belgian Official GazetteArticles of association with the signing rule25-10-2021deed 21363056
Peppol DirectoryRegistration for e-invoices24-11-20230208:0683469918
Sanctions lists EU, UN, US (OFAC) and UKComparison of the name16-11-2026no match

Method

Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.

Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 18-11-2026.

Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.

Payment terms. Supplier credit is the debt to suppliers divided by the year's purchases, times 365. Customer credit is the same for what customers still owe, against turnover.

Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.

The scores and ratios are Checked's own calculations, not a credit decision.

Storms Pharma · 0683.469.918 · credit report of 19-11-2026Page 6 of 6